The immunology of host defence peptides: Beyond antimicrobial activity

Nature Reviews Immunology

Volumn 16, Issue 5, 2016, Pages 321-334

  Hancock, Robert E W ^a   Haney, Evan F ^a   Gill, Erin E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEFENSIN; HOST DEFENSE PEPTIDE; IMMUNOMODULATING AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; IMMUNOLOGIC FACTOR;

AUTOIMMUNE DISEASE; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE; SYSTEMS BIOLOGY; WOUND HEALING; ANIMAL; DISEASE PREDISPOSITION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MICROFLORA; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE SUSCEPTIBILITY; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MICROBIOTA; SIGNAL TRANSDUCTION;

EID: 84964389619     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2016.29     Document Type: Review

References (128)

1. Hancock, R. E. W., & Sahl, H. G. Antimicrobial and host-defence peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551-1557 (2006).
2. Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11, 37-51 (2012).
3. Wang, G., Li, X., & Wang, Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 44, D1087-D1093 (2016).
4. Hilchie, A. L., Wuerth, K., & Hancock, R. E. W. Immune modulation by multifaceted cationic host defence (antimicrobial) peptides. Nat. Chem. Biol. 9, 761-768 (2013).
5. Scott, M. G. et al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25, 465-472 (2007).
6. Mansour, S. C., Pena, O. M., & Hancock, R. E. W. Host defence peptides: front-line immunomodulators. Trends Immunol. 35, 443-450 (2014).
7. Breuer, K. et al. InnateDB: systems biology of innate immunity and beyond-recent updates and continuing curation. Nucleic Acids Res. 41, D1228-D1233 (2013).
8. Xia, J., Gill, E. E., & Hancock, R. E. W. NetworkAnalyst for statistical, visual and network-based meta-Analysis of gene expression data. Nat. Protoc. 10, 823-844 (2015).
9. Hultmark, D., Steiner, H., Rasmuson, T., & Boman, H. G. Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur. J. Biochem. 106, 7-16 (1980).
10. Gallo, R. L., & Hooper, L. V. Epithelial antimicrobial defence of the skin and intestine. Nat. Rev. Immunol. 12, 503-516 (2012).
11. Ganz, T. Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect. Immun. 55, 568-571 (1987).
12. Ayabe, T. et al. Secretion of microbicidal α defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol. 1, 113-118 (2000).
13. Bowdish, D. M. et al. Impact of LL 37 on anti-infective immunity. J. Leukoc. Biol. 77, 451-459 (2005).
14. Vandamme, D., Landuyt, B., Luyten, W., & Schoofs, L. A comprehensive summary of LL 37, the factotum human cathelicidin peptide. Cell. Immunol. 280, 22-35 (2012).
15. Nijnik, A., & Hancock, R. E. W. The roles of cathelicidin LL 37 in immune defences and novel clinical applications. Curr. Opin. Hematol. 16, 41-47 (2009).
16. Wang, T. T. et al. Cutting edge: 1,25 Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173, 2909-2912 (2004).
17. Mily, A. et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS ONE 10, e0138340 (2015).
18. Mookherjee, N. et al. Systems biology evaluation of immune responses induced by human host defence peptide LL 37 in mononuclear cells. Mol. Biosyst. 5, 483-496 (2009).
19. Peyssonnaux, C. et al. Critical role of HIF 1α in keratinocyte defence against bacterial infection. J. Invest. Dermatol. 128, 1964-1968 (2008).
20. Yu, J. et al. Host defence peptide LL 37, in synergy with inflammatory mediator IL 1β, augments immune responses by multiple pathways. J. Immunol. 179, 7684-7691 (2007).
21. Lai, Y. et al. LL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAs. PLoS ONE 6, e26632 (2011).
22. Nijnik, A., Pistolic, J., Filewod, N. C. J., & Hancock, R. E. W. Signaling pathways mediating chemokine induction in keratinocytes by cathelicidin LL 37 and flagellin. J. Innate Immun. 4, 377-386 (2012).
23. Hurtado, P., & Peh, C. A. LL 37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J. Immunol. 184, 1425-1435 (2010).
24. Chen, X. et al. Human antimicrobial peptide LL 37 modulates proinflammatory responses induced by cytokine milieus and double-stranded RNA in human keratinocytes. Biochem. Biophys. Res. Commun. 433, 532-537 (2013).
25. van der Does, A. M. et al. LL 37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J. Immunol. 185, 1442-1449 (2010).
26. Davidson, D. J. et al. The cationic antimicrobial peptide LL 37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172, 1146-1156 (2004).
27. Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449, 564-569 (2007).
28. Chamilos, G. et al. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. Blood 120, 3699-3707 (2012).
29. Ries, M. et al. Identification of novel oligonucleotides from mitochondrial DNA that spontaneously induce plasmacytoid dendritic cell activation. J. Leukoc. Biol. 94, 123-135 (2013).
30. Elssner, A., Duncan, M., Gavrilin, M., & Wewers, M. D. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL 1β processing and release. J. Immunol. 172, 4987-4994 (2004).
31. Mookherjee, N. et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defence peptide LL 37. J. Immunol. 176, 2455-2464 (2006).
32. Jin, G. et al. An antimicrobial peptide regulates tumor-Associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS ONE 5, e10993 (2010).
33. Kandler, K. et al. The anti-microbial peptide LL 37 inhibits the activation of dendritic cells by TLR ligands. Int. Immunol. 18, 1729-1736 (2006).
34. Di Nardo, A. et al. Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J. Immunol. 178, 1829-1834 (2007).
35. Hazlett, L., & Wu, M. Defensins in innate immunity. Cell Tissue Res. 343, 175-188 (2011).
36. Semple, F., & Dorin, J. R. β-Defensins: multifunctional modulators of infection, inflammation and more?. J. Innate Immun. 4, 337-348 (2012).
37. Rodríuez-Garcí, M. et al. Human immature monocyte-derived dendritic cells produce and secrete α-defensins 1-3. J. Leukoc. Biol. 82, 1143-1146 (2007).
38. Yamamoto-Furusho, J. K., Barnich, N., Hisamatsu, T., & Podolsky, D. K. MDP NOD2 stimulation induces HNP 1 secretion, which contributes to NOD2 antibacterial function. Inflamm. Bowel Dis. 16, 736-742 (2010).
39. Negroni, A. et al. Activation of NOD2 mediated intestinal pathway in a pediatric population with Crohn?s disease. Inflamm. Bowel Dis. 15, 1145-1154 (2009).
40. Harder, J., Bartels, J., Christophers, E., & Schroder, J. M. Isolation and characterization of human β-defensin 3, a novel human inducible peptide antibiotic. J. Biol. Chem. 276, 5707-5713 (2001).
41. Garcí, J. R. et al. Human β-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. 15, 1819-1821 (2001).
42. Miles, K. et al. Dying and necrotic neutrophils are anti-inflammatory secondary to the release of α-defensins. J. Immunol. 183, 2122-2132 (2009).
43. Soehnlein, O. et al. Neutrophil primary granule proteins HBP and HNP1 3 boost bacterial phagocytosis by human and murine macrophages. J. Clin. Invest. 118, 3491-3502 (2008).
44. Niyonsaba, F. et al. Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J. Invest. Dermatol. 127, 594-604 (2007).
45. Boniotto, M. et al. Human β-defensin 2 induces a vigorous cytokine response in peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 50, 1433-1441 (2006).
46. Funderburg, N. et al. Human β defensin 3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc. Natl Acad. Sci. USA 104, 18631-18635 (2007).
47. Chaly, Y. V. et al. Neutrophil α-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur. Cytokine Netw. 11, 257-266 (2000).
48. Tewary, P. et al. β Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN α production by human plasmacytoid dendritic cells, and promote inflammation. J. Immunol. 191, 865-874 (2013).
49. Economopoulou, M. et al. Inhibition of pathologic retinal neovascularization by α-defensins. Blood 106, 3831-3838 (2005).
50. Chavakis, T. et al. Regulation of neovascularization by human neutrophil peptides (α-defensins): a link between inflammation and angiogenesis. FASEB J. 18, 1306-1308 (2004).
51. Lu, W., & de Leeuw, E. Pro-inflammatory and pro-Apoptotic properties of Human Defensin 5. Biochem. Biophys. Res. Commun. 436, 557-562 (2013).
52. Nagaoka, I., Niyonsaba, F., Tsutsumi-Ishii, Y., Tamura, H., & Hirata, M. Evaluation of the effect of human β-defensins on neutrophil apoptosis. Int. Immunol. 20, 543-553 (2008).
53. Semple, F. et al. Human β-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur. J. Immunol. 40, 1073-1078 (2010).
54. Semple, F. et al. Human β defensin 3 affects the activity of pro-inflammatory pathways associated with MyD88 and TRIF. Eur. J. Immunol. 41, 3291-3300 (2011).
55. Suarez-Carmona, M. et al. Np63 isoform-mediated β defensin family up regulation is associated with (lymph)angiogenesis and poor prognosis in patients with squamous cell carcinoma. Oncotarget 5, 1856-1868 (2014).
56. Baroni, A. et al. Antimicrobial human β-defensin 2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells. Peptides 30, 267-272 (2009).
57. Pena, O. M. et al. Synthetic cationic peptide IDR 1018 modulates human macrophage differentiation. PLoS ONE 8, e52449 (2013).
58. Mansour, S. C., de la Fuente-Nez, C., & Hancock, R. E. Peptide IDR 1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J. Pept. Sci. 21, 323-329 (2015).
59. Zhao, A., Lu, W., & de Leeuw, E. Functional synergism of Human Defensin 5 and Human Defensin 6. Biochem. Biophys. Res. Commun. 467, 967-972 (2015).
60. B?chau, A. S. et al. The host defence peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J. Immunol. 184, 369-378 (2010).
61. Taudien, S. et al. Association studies of the copy-number variable ?-defensin cluster on 8p23.1 in adenocarcinoma and chronic pancreatitis. BMC Res. Notes 5, 629 (2012).
62. Han, Q. et al. Human β-defensin 1 suppresses tumor migration and invasion and is an independent predictor for survival of oral squamous cell carcinoma patients. PLoS ONE 9, e91867 (2014).
63. Winter, J. et al. Human β-defensin 1,-2, and-3 exhibit opposite effects on oral squamous cell carcinoma cell proliferation. Cancer Invest. 29, 196-201 (2011).
64. Gunes, M. et al. Plasma human neutrophil proteins 1,-2, and-3 levels in patients with bladder cancer. J. Cancer Res. Clin. Oncol. 139, 195-199 (2012).
65. Chuang, C. M., Monie, A., Wu, A., Mao, C. P., & Hung, C. F. Treatment with LL 37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum. Gene Ther. 20, 303-313 (2009).
66. Kuroda, K., Okumura, K., Isogai, H., & Isogai, E. The human cathelicidin antimicrobial peptide LL 37 and mimics are potential anticancer drugs. Front. Oncol. 5, 344 (2015).
67. Gaspar, D., Veiga, A. S., & Castanho, M. A. From antimicrobial to anticancer peptides. A review. Front. Microbiol. 4, 294 (2013).
68. von Haussen, J. et al. The host defence peptide LL 37/hCAP 18 is a growth factor for lung cancer cells. Lung Cancer 59, 12-23 (2008).
69. Sainz, B. et al. Microenvironmental hCAP 18/LL 37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut 64, 1921-1935 (2015).
70. Lecaille, F., Lalmanach, G., & Andrault, P. M. Antimicrobial proteins and peptides in human lung diseases: a friend and foe partnership with host proteases. Biochimie 122, 151-168 (2016).
71. Ratjen, F., & D?ring, G. Cystic fibrosis. Lancet 361, 681-689 (2003).
72. Chen, C. I. U., Schaller-Bals, S., Paul, K. P., Wahn, U., & Bals, R. β defensins and LL 37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J. Cyst. Fibros. 3, 45-50 (2004).
73. Bergsson, G. et al. LL 37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J. Immunol. 183, 543-551 (2009).
74. Mayer, M. L. et al. Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells. J. Immunol. 190, 1227-1238 (2013).
75. de la Fuente-Nez, C., Reffuveille, F., Haney, E. F., Straus, S. K., & Hancock, R. E. W. Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathog. 10, e1004152 (2014).
76. Xiao, W., Hsu, Y. P., Ishizaka, A., Kirikae, T., & Moss, R. B. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest 128, 2316-2326 (2005).
77. Paone, G. et al. Human neutrophil peptides sputum levels in symptomatic smokers and COPD patients. Eur. Rev. Med. Pharmacol. Sci. 15, 556-562 (2011).
78. Olin, J. T., & Wechsler, M. E. Asthma: pathogenesis and novel drugs for treatment. BMJ 349, g5517 (2014).
79. Sun, J., Dahlén, B., Agerberth, B., & Haeggström, J. Z. The antimicrobial peptide LL 37 induces synthesis and release of cysteinyl leukotrienes from human eosinophils-implications for asthma. Allergy 68, 304-311 (2013).
80. Rohde, G. et al. CXC chemokines and antimicrobial peptides in rhinovirus-induced experimental asthma exacerbations. Clin. Exp. Allergy 44, 930-939 (2014).
81. Brauner, H. et al. Markers of innate immune activity in patients with type 1 and type 2 diabetes mellitus and the effect of the anti-oxidant coenzyme Q10 on inflammatory activity. Clin. Exp. Immunol. 177, 478-482 (2014).
82. Diana, J. et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 19, 65-73 (2013).
83. Allen, J. S. et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T cells through immune complex capture. Diabetes 58, 138-145 (2009).
84. Sun, J. et al. Pancreatic β cells limit autoimmune diabetes via an immunoregulatory antimicrobial peptide expressed under the influence of the gut microbiota. Immunity 43, 304-317 (2015).
85. Gonzalez-Curiel, I. et al. Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus. Hum. Immunol. 72, 656-662 (2011).
86. Rivas-Santiago, B. et al. Expression of antimicrobial peptides in diabetic foot ulcer. J. Dermatol. Sci. 65, 19-26 (2012).
87. Kahlenberg, J. M., & Kaplan, M. J. Little peptide, big effects: the role of LL 37 in inflammation and autoimmune disease. J. Immunol. 191, 4895-4901 (2013).
88. Hall, J. C., & Rosen, A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat. Rev. Rheumatol. 6, 40-49 (2010).
89. Murakami, M. et al. Cathelicidin anti-microbial peptide expression in sweat, an innate defence system for the skin. J. Invest. Dermatol. 119, 1090-1095 (2002).
90. Nardo, A. D., Vitiello, A., & Gallo, R. L. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170, 2274-2278 (2003).
91. Frohm, M. et al. The expression of the gene coding for the antibacterial peptide LL 37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272, 15258-15263 (1997).
92. Clausen, M. L., Slotved, H. C., Krogfelt, K. A., Andersen, P. S., & Agner, T. In vivo expression of antimicrobial peptides in atopic dermatitis. Exp. Dermatol. 25, 3-9 (2016).
93. Nomura, I. et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J. Immunol. 171, 3262-3269 (2003).
94. Harder, J. et al. Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J. Invest. Dermatol. 130, 1355-1364 (2010).
95. Ballardini, N. et al. Enhanced expression of the antimicrobial peptide LL 37 in lesional skin of adults with atopic eczema. Br. J. Dermatol. 161, 40-47 (2009).
96. Kopfnagel, V., Harder, J., & Werfel, T. Expression of antimicrobial peptides in atopic dermatitis and possible immunoregulatory functions. Curr. Opin. Allergy Clin. Immunol. 13, 531-536 (2013).
97. Ong, P. Y. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151-1160 (2002).
98. Lande, R. et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur. J. Immunol. 45, 203-213 (2015).
99. Nestle, F. O. et al. Plasmacytoid predendritic cells initiate psoriasis through interferon α production. J. Exp. Med. 202, 135-143 (2005).
100. Morizane, S. et al. Cathelicidin antimicrobial peptide LL 37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J. Invest. Dermatol. 132, 135-143 (2012).
101. Lande, R. et al. The antimicrobial peptide LL37 is a T cell autoantigen in psoriasis. Nat. Commun. 5, 5621 (2014).
102. Nijnik, A., & Hancock, R. Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerg. Health Threats J. 2, e1 (2009).
103. Gonzalez-Curiel, I. et al. 1,25 dihydroxyvitamin D3 induces LL 37 and HBD 2 production in keratinocytes from diabetic foot ulcers promoting wound healing: an in vitro model. PLoS ONE 9, e111355 (2014).
104. Raftery, T. et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn?s disease: results from a randomised double-blind placebo-controlled study. United European Gastroenterol. J. 3, 294-302 (2015).
105. Mily, A. et al. Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL 37 in human macrophages: a dose finding study for treatment of tuberculosis. BMC Pulm. Med. 13, 23 (2013).
106. Gambichler, T. et al. Expression of antimicrobial peptides and proteins in etanercept-Treated psoriasis patients. Regul. Pept. 167, 163-166 (2011).
107. Heilborn, J. D. et al. The cathelicidin anti-microbial peptide LL 37 is involved in re epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 120, 379-389 (2003).
108. Shaykhiev, R. et al. Human endogenous antibiotic LL 37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L842-L848 (2005).
109. Tokumaru, S. et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL 37. J. Immunol. 175, 4662-4668 (2005).
110. Niyonsaba, F. et al. Antimicrobial peptides human β defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J. Invest. Dermatol. 127, 594-604 (2006).
111. Gr?nberg, A., Mahlapuu, M., St?hle, M., Whately-Smith, C., & Rollman, O. Treatment with LL 37 is safe and effective in enhancing healing of hard to heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 22, 613-621 (2014).
112. Hirsch, T. et al. Human β-defensin 3 promotes wound healing in infected diabetic wounds. J. Gene Med. 11, 220-228 (2009).
113. Steinstraesser, L. et al. Innate defence regulator peptide 1018 in wound healing and wound infection. PLoS ONE. 7, e39373 (2012).
114. Caterino, J. M. et al. A Prospective, observational pilot study of the use of urinary antimicrobial peptides in diagnosing emergency department patients with positive urine cultures. Acad. Emerg. Med. 22, 1226-1230 (2015).
115. Albrethsen, J., M?ller, C. H., Olsen, J., Raskov, H., & Gammeltoft, S. Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. Eur. J. Cancer 42, 3057-3064 (2006).
116. Kim, D. H. et al. Antimicrobial peptide, lumbricusin, ameliorates motor dysfunction and dopaminergic neurodegeneration in a mouse model of parkinson?s disease. J. Microbiol. Biotechnol. 25, 1640-1647 (2015).
117. Zhang, Z., & Shively, J. E. Generation of novel bone forming cells (monoosteophils) from the cathelicidin-derived peptide LL 37 treated monocytes. PLoS ONE 5, e13985 (2010).
118. Bevins, C. L., & Salzman, N. H. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat. Rev. Microbiol. 9, 356-368 (2011).
119. Cullen, T. W. et al. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science 347, 170-175 (2015).
120. Gellatly, S. L., Needham, B., Madera, L., Trent, M. S., & Hancock, R. E. W. The Pseudomonas aeruginosa PhoP-PhoQ two-component regulatory system is induced upon interaction with epithelial cells and controls cytotoxicity and inflammation. Infect. Immun. 80, 3122-3131 (2012).
121. Jones, E. A., Kananurak, A., Bevins, C. L., Hollox, E. J., & Bakaletz, L. O. Copy number variation of the β defensin gene cluster on chromosome 8p influences the bacterial microbiota within the nasopharynx of otitis-prone children. PLoS ONE 9, e98269 (2014).
122. Guo, L. et al. Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. Proc. Natl Acad. Sci. USA 112, 7569-7574 (2015).
123. Gardy, J. L., Lynn, D. J., Brinkman, F. S. L., & Hancock, R. E. W. Enabling a systems biology approach to immunology: focus on innate immunity. Trends Immunol. 30, 249-262 (2009).
124. Haney, E. F., Mansour, S. C., Hilchie, A. L., de la Fuente-Nez, C., & Hancock, R. E. W. High throughput screening methods for assessing antibiofilm and immunomodulatory activities of synthetic peptides. Peptides 71, 276-285 (2015).
125. Cherkasov, A. et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem. Biol. 4, 65-74 (2009).
126. Barrett, T. et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 41, D991-D995 (2013).
127. Suarez-Carmona, M., Hubert, P., Delvenne, P., & Herfs, M. Defensins: ?simple? antimicrobial peptides or broad-spectrum molecules?. Cytokine Growth Factor Rev. 26, 361-370 (2015).
128. Croft, D. et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 42, D472-D477 (2014).